Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher on modest rise in inflation
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
Vanda Pharmaceuticals (VNDA) Reports In-Line Q1 EPS, Revenues Miss
May 5, 2021 4:13 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $62.67 million versus the consensus estimate of $68.5 million.
"Despite seasonal and global challenges, we recorded another quarter of strong revenue across our... More
